Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-01-06
2010-12-21
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S232800, C514S317000, C514S649000, C549S467000
Reexamination Certificate
active
07855195
ABSTRACT:
The present invention relates to methods of treating of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena- . . . ) using compounds and compositions of compounds having D4 and/or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for. The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and/or (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and/or (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and/or biological compounds.
REFERENCES:
patent: 4797419 (1989-01-01), Moos et al.
patent: 5364857 (1994-11-01), Bode Greuel
patent: 5446070 (1995-08-01), Mantelle
patent: 5554383 (1996-09-01), Dodman
patent: 5635213 (1997-06-01), Nystrom et al.
patent: 5759837 (1998-06-01), Kuhajda et al.
patent: 5762960 (1998-06-01), Dodman
patent: 5780474 (1998-07-01), Brocco et al.
patent: 6150353 (2000-11-01), Broekkamp et al.
patent: 6191133 (2001-02-01), Coppen
patent: 6300354 (2001-10-01), Steiner et al.
patent: 6358698 (2002-03-01), Weiner et al.
patent: 2002/0086899 (2002-07-01), Sanchez et al.
patent: 2003/0032636 (2003-02-01), Cremers et al.
patent: 2004/0002482 (2004-01-01), Dudley et al.
patent: 2004/0213816 (2004-10-01), Weiner et al.
patent: 2005/0119249 (2005-06-01), Buntinx
patent: 2005/0119253 (2005-06-01), Buntinx
patent: 2005/0148018 (2005-07-01), Weiner et al.
patent: 2005/0203130 (2005-09-01), Buntinx
patent: 2005/0261278 (2005-11-01), Weiner et al.
patent: 2005/0261340 (2005-11-01), Weiner et al.
patent: 2005/0288328 (2005-12-01), Weiner et al.
patent: 2006/0199842 (2006-09-01), Weiner et al.
patent: 2006/0264465 (2006-11-01), Weiner et al.
patent: 2006/0264466 (2006-11-01), Weiner et al.
patent: 2007/0078162 (2007-04-01), Buntinx
patent: 2461248 (2009-09-01), None
patent: 40 39 631 (1992-06-01), None
patent: 4039631 (1992-06-01), None
patent: 1 541 197 (2009-03-01), None
patent: WO 98/11897 (1998-03-01), None
patent: WO 98/43646 (1998-10-01), None
patent: WO 00/64441 (2000-11-01), None
patent: 0141701 (2001-06-01), None
patent: WO 01/41701 (2001-06-01), None
patent: WO 01/98298 (2001-12-01), None
patent: WO 02/051833 (2002-07-01), None
Prinssen et al. (E J of Pharmacology, 388, 2000, 57-67).
Meyer et al. J of Pharmacokinetics and Biopharmaceutics, 24, 5, 1996.
Hubble J P et al., entitled “Pre-clinical studies of pramipexole: clinical relevance,” European Journal of Neurology Supplement, 2000, vol. 7 (Suppl. 1), pp. 15-20.
Silver D E et al., entitled “Initiating therapy for Parkinson's disease,” Neurology, 1998, vol. 50 (Suppl. 6), pp. S18-S22.
www.biam2.org/www/Sub2783.html, entitled “Pipamperone Dichlorhydrate,” Nov. 12, 2000, 1-4.
www.adiph.org/pic/pedia-neuroleptiques.pdf, entitled “Medicaments Psychotropes: Posologies Chez L'Enfant et L'Adolescent,” Aug. 2001, 1-3.
Heiser P et al., entitled “The selective serotonin reuptake inhibitors and the newer antidepressants in child and adolescent psychiatry,” Zeitschrift fur Kinder—und Jugendpsychiatrie und Psychotherpie Switzerland 30: 2002, 173-183.
Carlier PR et al., Synthesis of a Potent Wide-Spectrum Serotonin-, Norepinephrine-, Dopamine- reuptake inhibitor (SNDRI) and a species-selective dopamine reuptake inhibitor based on the gamma-amino alcohol functional group, Bioorgan. Medicin. Chem. Let. 8, 1998, 487-492.
Fitzgerald K D et al., entitled “Risperidone Augmentation of Serotonin Reuptake Inhibitor Treatment of Pediatric Obsessive Compulsive Disorder,” Journal of Child and Adolescent Psychopharmacology, vol. 9, No. 2, 1999, 115-123.
McDougle C J et al., entitled “A Double-blind. Placebo-Dontrolled Study of Risperidone Addition in Serotonin Reuptake Inhibitor-Refractory Obsessive-complusive Disorder,” Arch Gen Psychiatry, vol. 57, Aug. 2000, 794-801.
Maina G et al., entitled “Antipsychotic agumentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued,” Int. Clin. Psychopharm, 18, 2003, 23-28.
Hirose S et al., entitled “An Open Pilot Study Combining Risperidone and a Selective Serotonin Reuptake Inhibitor as Initial Antidepresant Therapy,” J. Clin. Psych. 63, 2002, 733-736.
Truffinet P et al., Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am J. Psychiatry 156: 419-425, 1999.
Schindler T et al., entitled “Palliative medical management in anxiety and depression,” Zeitschrift Fur Allgemeinmedizin, vol. 74, No. 21, Nov. 5, 1998, pp. 973-978.
Volmat R et al., entitled “The treatment of depressions by Cledial. Evolution and clinical state and handwriting,” Psychologie Medicale, vol. 18, No. 10, 1986, pp. 1615-1622.
Fouks et al., entitled “Treatment of character disorders with a new butyrophenone: R. 3345 or pipamperone,” Annales Medico-Psychologiques, vol. 124, No. 5, 1966, pp. 677-681.
Squelart P et al., entitled “Pipamperone (Dipiperon), a useful sedative neuroleptic drug in troublesome chronic psychotic patients,” Acta Psychiatrica Belgica, vol. 77, No. 2, Mar. 1977, pp. 284-293.
Koch H J et al., entitled “Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapinr and tiapride,” International Journal of Clinical Practice, vol. 57, No. 2, Mar. 2003, pp. 147-149.
Diebold K et al., entitled “Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?” Pharmacopsychiatry, 1998, 31/2, pp. 60-67.
Grozinger M et al., entitled “Melperone is an inhibitor of the CYP2D6 catalyzed 0-demethylation of venlafaxine,” Pharmacopsychiatry, vol. 36, No. 1, Jan. 3003, pp. 3-6.
Perugi G et al., entitled “Effectiveness of Adjunctive Gabapentin in Resistant Bipolar Disorder: Is it due to anxious-alcohol abuse comorbidity?” Journal of clinical Psychopharmacology, vol. 22, No. 6, 2002, pp. 584-591.
Wieling W et al., entitled “Initial orthostatic hypotension as a cause of recurrent syncope: A case report,” Clinical Autonomic Research, vol. 11, No. 4, 2001, pp. 269-270.
Database Pharmaprojects ′Online! PJB Publications Ltd., Dec. 1999. Caesar accession No. 1498.
Adler L et al., entitled “Praxis Der Stationaeren Akutbehandlung Von Manien Retrospektive Vergleichsuntersuchung An Je 100 Patienten Zweier Psychiatrischer Sentren Practice of In-Patient Acute Treatment of Manias,” Fortschritte Der Neurologie.
Psychiatrie, Stuttgart, vol. 62, No. 12, 1994, pp. 479-488.
Ansoms C et al., entitled “Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamerone (Dipiperon),” Acta Psychiatrica Scandinavica, vol. 55, No. 2, Feb. 1977, pp. 116-122.
Leysen J E et al., entitled “Receptor interactions of new antipsychotics: Relation to Pharmacodynamic and Clinical Effects,” International Journal of Psychiatry in Clinical Practice, vol. 2, No. 1, 1998, pp. S03-S17.
Vanhoenacker P et al., entitled “Efficient Expression of the Human Dopamine D4.2 Receptor: Positive Influence of Pipamperone on Expression Levels,” Abstracts of the Society for Neuroscience, vol. 26, No. 1/2, 2000.
Schotte A et al., entitled “Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding,” Psychopharmacology, vol. 124, No. 1-2, 1996, pp. 57-73.
Woggon B, entitled “Pharmakologische dep
Amster Rothstein & Ebenstein LLP
Padmanabhan Sreeni
PharmaNeuroBoost N.V.
Ramachandran Umamaheswari
LandOfFree
Method of treating mental disorders using D4 and 5-HT2A... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating mental disorders using D4 and 5-HT2A..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating mental disorders using D4 and 5-HT2A... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4221914